WARF currently is working with more than 50 active startups whose business markets include therapeutics, research tools, biotechnology, medical devices, food and agriculture, engineering, computer, stem cell and clean technologies. WARF currently holds equity in more than 30 of these companies. Some of WARF's startup companies have achieved IPO status as publicly-traded companies and have been acquired by large, well established companies, such as Roche and Hologic.
Successful Exits
 |
Imago was acquired by Ametek Inc. in 2010. Imago Scientific Instruments Corporation was founded by Dr. Tom Kelly, Professor of Materials Science and Engineering and Director of the Materials Science Center in 1998. Since then Imago has become the world leader in 3-D structure and composition analysis at the nanoscale by developing the award-winning Local Electrode Atom Probe (LEAP™) microscope. Imago's first shipment was made to Oak Ridge National Laboratory in June 2003. It currently has 40 employees in Madison, Wis., a world-wide customer base with over 25 instruments around the world and global technology affiliations. Imago's LEAP revolutionized the field of atom-probe tomography (R&D 100 Award 2004), and it was the first to commercialize a laser atom probe (R&D 100 Award 2006) and a large-angle reflectron LEAP (R&D 100 Award 2008). In April 2008, Imago and FEI Company, the world's leading manufacturer of electron microscopes and focused-ion-beam instruments, announced a strategic partnership for sales and marketing of Imago's LEAP.
 |
Hologic holds the number one position in nine technology areas serving woman's health, including breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing and osteoporosis detection. Hologic believes that the health issues facing women today deserve and demand the singular dedication of a passionate company.
 |
Roche NimbleGen Inc. is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services.
 |
Mirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products.
Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for its novel research reagents.
